Avalo Therapeutics, Inc. (NASDAQ:AVTX) Stock Rated “Moderate Buy” by Sell-Side Analysts

Avalo Therapeutics, Inc. (NASDAQ:AVTX) has been assigned an average recommendation of “Moderate Buy” from the fourteen analysts that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $36.82.

A number of equities research analysts have weighed in on AVTX shares. Oppenheimer set a $16.00 price target on shares of Avalo Therapeutics in a report on Monday, October 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avalo Therapeutics in a research note on Wednesday, November 4th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Avalo Therapeutics in a report on Wednesday, September 16th. Wall Street Zen raised shares of Avalo Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 7th. Finally, HC Wainwright cut shares of Avalo Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, October 23rd.

Insider Buying and Selling at Avalo Therapeutics

In other Avalo Therapeutics news, CFO Christopher Sullivan sold 12,394 shares of Avalo Therapeutics stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $16.33, for a total transaction of $202,394.02. Following the transaction, the chief financial officer directly owned 39,900 shares in the company, valued at approximately $651,567. The trade was a 23.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 23,258 shares of company stock valued at $395,434 over the last quarter. Company insiders own 4.46% of the company’s stock.

Hedge Funds Weigh In On Avalo Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Seven Fleet Capital Management LP boosted its holdings in Avalo Therapeutics by 34.3% during the second quarter. Seven Fleet Capital Management LP now owns 770,765 shares of the company’s stock valued at $14,244,000 after acquiring an additional 196,882 shares during the period. Wellington Management Group LLP bought a new position in shares of Avalo Therapeutics in the second quarter worth about $1,945,000. Renaissance Technologies LLC increased its stake in shares of Avalo Therapeutics by 556.4% in the first quarter. Renaissance Technologies LLC now owns 120,114 shares of the company’s stock worth $1,793,000 after purchasing an additional 101,814 shares during the period. DV Trading LLC bought a new position in shares of Avalo Therapeutics in the first quarter worth about $5,376,000. Finally, Sei Investments Co. acquired a new position in shares of Avalo Therapeutics during the 1st quarter worth about $849,000. 87.06% of the stock is currently owned by hedge funds and other institutional investors.

Avalo Therapeutics Trading Up 0.8%

Avalo Therapeutics stock traded up $0.06 during midday trading on Friday, reaching $7.76. 974,092 shares of the stock traded hands, compared to its average volume of 3,339,771. Avalo Therapeutics has a fifty-two week low of $6.53 and a fifty-two week high of $24.27. The firm has a market cap of $448.68 million, a price-to-earnings ratio of -3.08 and a beta of 0.75. The firm has a fifty day moving average price of $12.33 and a two-hundred day moving average price of $15.64.

Avalo Therapeutics (NASDAQ:AVTX) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.25. Analysts anticipate that Avalo Therapeutics will post -2.52 earnings per share for the current year.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for immune-mediated and inflammatory diseases. The company does not have marketed products and is centered on advancing drug candidates through clinical development. Its lead candidate, AVTX-009, is a monoclonal antibody that targets interleukin-1 beta (IL-1β), an inflammatory signaling protein. Avalo is developing the therapy for hidradenitis suppurativa, a chronic inflammatory skin disease, and has described potential applications in other inflammatory conditions.